Short answer
Monopar Therapeutics (MNPR) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$5M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$5M
- −116.6% YoY · −36.5% QoQ
- EPS (diluted)
- −$0.62
- −77.1% YoY · −34.8% QoQ
Source: XBRL data from the Monopar Therapeutics (MNPR) Q2 2026 10-Q on SEC EDGAR. USD.
Monopar Therapeutics Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved drugs and no revenues generated
- Cash, equivalents and investments $134.3M at June 30, 2026
- Funds expected sufficient through December 31, 2027 for ALXN1840, MNPR-101 trials and pipeline R&D
- ALXN1840 rolling NDA submission initiated July 22, 2026, completion anticipated within months
- Key headwind: FDA acceptance or approval of ALXN1840 NDA not assured
Risk Factors
- No Risk Factors section provided; excerpt contains only Item 5 insider trading-plan disclosures
- Executive and director plans authorize sales of up to 91,289 shares collectively
- CEO plan covers up to 47,309 shares and terminates May 31, 2027
- CFO plan covers up to 615 shares and terminates May 31, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monopar Therapeutics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.